RITE3
LIVE

Serial Number

98727351

Owner

SEED Therapeutics US, Inc.

Attorney

Ian W. Gillies

First Use Date

Jan 28, 2025

Filing Date

Aug 30, 2024

Add to watchlist:

No watchlists yet
View on USPTO

RITE3 Trademark

Serial Number: 98727351 • Registration: 8245651

RITE3 is a trademark filed by SEED Therapeutics US, Inc. on August 30, 2024. The trademark is classified under Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

SEED Therapeutics US, Inc. (4 trademarks)

411 Swedeland Road
King of Prussia, PA 19406

Entity Type: 03

Trademark Details

Filing Date

August 30, 2024

Registration Date

May 5, 2026

First Use Anywhere

January 28, 2025

First Use in Commerce

January 28, 2025

Published for Opposition

August 19, 2025

Goods & Services

drug discovery, pharmaceutical drug development, and drug validation services in the field of targeted disease-causing or disease-associated protein degradation; pharmaceutical research and development services, in particular for identifying ubiquitin ligases; providing medical research and scientific information related to ubiquitin ligase identification and targeted disease-causing or disease-associated protein degradation in the fields of pharmaceuticals, biological life sciences, chemistry, biochemistry, biotechnology, and clinical trials; providing scientific, and medical research information related to targeted disease-causing or disease-associated protein degradation in the field of pharmaceutical and clinical trials via the internet; consulting services in the fields of pharmaceutical research, biological life sciences, pharmaceutical chemistry, biochemistry, biotechnology, clinical trials, all related to targeted disease-causing or disease-associated protein degradation; research and development of new products in the field of targeted disease-causing or disease-associated protein degradation and the identification of ubiquitin ligases; pharmaceutical, scientific, medical, and clinical research and development services in the field of targeted disease-causing or disease-associated protein degradation; providing information about scientific, pharmaceutical, clinical, and medical research, namely, drug discovery, development and validation information related to a method of ligase selection to discover molecules and drugs that cause targeted disease-causing or disease-associated protein degradation; Scientific and technological services, namely, technical biology consulting services, in particular for identifying ubiquitin ligases

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 5, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
May 5, 2026 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Apr 14, 2026 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Apr 14, 2026 CNPR
SOU TEAS EXTENSION RECEIVED
Apr 13, 2026 EEXT
STATEMENT OF USE PROCESSING COMPLETE
Apr 3, 2026 SUPC
USE AMENDMENT FILED
Oct 15, 2025 IUAF
TEAS STATEMENT OF USE RECEIVED
Oct 15, 2025 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 14, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 19, 2025 NPUB
PUBLISHED FOR OPPOSITION
Aug 19, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 13, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 16, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 12, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 12, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 12, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 13, 2025 GNRN
NON-FINAL ACTION E-MAILED
Mar 13, 2025 GNRT
NON-FINAL ACTION WRITTEN
Mar 13, 2025 CNRT
ASSIGNED TO EXAMINER
Mar 13, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 12, 2025 NWOS
NEW APPLICATION ENTERED
Aug 30, 2024 NWAP